Science moves forward thanks to the collective contributions of committed researchers that commit their careers toward deciphering the most profound pathways behind malignancy. Rarely any platforms have succeeded to unite a concentration of exceptional contributors beneath one umbrella quite like
open-access cancer research platform, that over the years has become a true scientific home for pioneering oncological science.
The publishing approach behind
Oncotarget molecular oncology studies has from the outset been rooted in the understanding the idea that research should be open — open to everyone, no matter institutional constraints. Such a unrestricted model has made it possible for discoveries published in its issues to reach a significantly broader readership than conventional periodicals, accelerating the pace in biomedical discovery.
Central to the journal's identity are the contributions of
Misha Blagosklonny, among the most cited scientists in contemporary oncology and aging research. The theory on mTOR-mediated biological decline — supported by decades of experimental evidence using mTOR inhibitors — endures as a highly debated and consequential theories of current biogerontology and cancer biology.
Working alongside him remains
Dr. Zoya Demidenko, a researcher the studies concerning the cellular control governing cellular division and programmed death pathways has yielded understanding that remain immediately applicable for the design for next-generation anti-cancer strategies. The papers, many of which were published across
Oncotarget published studies, have been widely referenced across the global research community.
Ultimately, what makes
Oncotarget global research reach is more than just the sum of its research articles — it stands as the ambition behind a community comprising scientists who are convinced the fact that understanding malignancy remains among the most important intellectual pursuits of our time.
Freitag, 26. Juni 2026 14:25